# US 2026/0098085 A1 · Methods for treating age-related macular degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098085 A1
- Document ID: US20260098085A1
- Status: Published application
- Kind: A1
- Application number: 19/249,026
- Filed: 2025-06-25
- Published: 2026-04-09
- Earliest claimed: 2014-11-07
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Margarita Gekkieva; Peter Sallstig; Werner Schmidt; James Warburton; Andreas Weichselberger
- Web page: https://patentgrep.com/patent/US20260098085A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61B 3/12: for looking at the eye fundus, e.g. ophthalmoscopes (A61B3/13 takes precedence)
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

## Claims

### Claim at position 1

-10. (canceled)

### Claim 11

A method for inhibiting choroidal neovascularization (CNV) in a patient in need thereof, the method comprising administering an anti-VEGF antagonist to the patient at monthly intervals for three doses, followed by administering to the patient one dose every 12 weeks or every 8 weeks, wherein each dose of the anti-VEGF antagonist is at least 3 mg, wherein the anti-VEGF antagonist comprises a heavy chain variable domain having the sequence as set forth in SEQ ID NO: 1 and a light chain variable domain having the sequence as set forth in SEQ ID NO: 2.

### Claim 12 (depends on 11)

The method of claim 11, wherein after the administering of the anti-VEGF antagonist for three doses at monthly intervals, the patient is administered one dose every 12 weeks.

### Claim 13 (depends on 11)

The method of claim 11, wherein after the administering of the anti-VEGF antagonist for three doses at monthly intervals, the patient is administered one dose every 8 weeks.

### Claim 14 (depends on 11)

The method of claim 11, further comprising an assessment of one or more criteria selected from: best-corrected visual acuity (BCVA), visual acuity (VA), central subfield thickness (CSFT) as measured by optical coherence tomography (OCT), and the presence of new or worsening intraretinal cysts/intraretinal fluid (IRC/IRF).

### Claim 15 (depends on 14)

The method of claim 14, wherein the outcome of the assessment of one or more criteria determines whether the patient is administered one dose every 12 weeks or one dose every 8 weeks.

### Claim 16 (depends on 11)

The method of claim 11, wherein each does of the anti-VEGF antagonist is 3 mg.

### Claim 17 (depends on 11)

The method of claim 11, wherein each does of the anti-VEGF antagonist is 6 mg.

### Claim 18 (depends on 11)

The method of claim 11, wherein the anti-VEGF antagonist is administered by intravitreal injection.

### Claim 19 (depends on 18)

The method of claim 18, wherein each does of the anti-VEGF antagonist is administered as a 50 μL intravitreal injection.

### Claim 20 (depends on 11)

The method of claim 11, wherein the anti-VEGF antagonist comprises the sequence of SEQ ID NO: 3.

### Claim 21 (depends on 20)

The method of claim 20, wherein the anti-VEGF antagonist is brolucizumab.

### Claim 22 (depends on 11)

The method of claim 11, wherein the patient has age-related macular degeneration (AMD).

### Claim 23 (depends on 12)

The method of claim 12, wherein a 12-week treatment interval is switched to an 8-week treatment interval if one or more of the following criteria are met:
a) decrease in BCVA of ≥5 letters compared to baseline, at a specified time point,
b) decrease in BCVA of ≥5 letters at a specified second time point compared to a specified first time point,
c) VA decline of ≥3 letters and CSFT increase ≥75 μm, at a specified second time point compared to a specified first time point, and
d) new or worsening intraretinal cysts (IRC)/intraretinal fluid (IRF) at a specified second time point compared to a specified first time point.

### Claim 24 (depends on 12)

The method of claim 12, wherein a 12-week treatment interval is switched to an 8-week treatment interval if one or more of the following criteria are met:
e) decrease in BCVA of ≥5 letters, due to neovascular age-related macular degeneration (nAMD) disease activity, at Week 16 compared to baseline,
f) decrease in BCVA of ≥5 letters, due to nAMD disease activity, at Week 16 compared to Week 12,
g) VA decline of ≥3 letters and CSFT increase ≥75 μm, at Week 16 compared to Week 12, and
h) new or worsening intraretinal cysts (IRC)/intraretinal fluid (IRF) at Week 16 compared to Week 12.

### Claim 25 (depends on 12)

The method of claim 12, wherein a 12-week treatment interval is switched to an 8-week treatment interval if the following criteria is met: decrease in BCVA of ≥5 letters at Week 20, 32, or 44 compared to Week 12.

### Claim 26 (depends on 12)

The method of claim 12, wherein a 12-week treatment interval is switched to an 8-week treatment interval if the following criteria is met: decrease in BCVA of ≥5 letters at Week 56, 68, or 80 compared to Week 12.

### Claim 27 (depends on 13)

The method of claim 13, wherein an 8-week treatment interval is switched to a 12-week treatment interval if one or more of the following criteria are not met:
a) decrease in BCVA of ≥5 letters at a specified second time point compared to a specified first time point, and
b) new or worsening intraretinal cysts (IRC)/intraretinal fluid (IRF) at a specified second time point compared to a specified first time point.

### Claim 28 (depends on 13)

The method of claim 13, wherein an 8-week treatment interval is switched to a 12-week treatment interval if one or more of the following criteria are not met:
a) decrease in BCVA of ≥5 letters at Week 48 compared to Week 32, and
b) new or worsening intraretinal cysts (IRC)/intraretinal fluid (IRF) at Week 48 compared to Week 32.

### Claim 29 (depends on 13)

The method of claim 13, wherein the patient has a beneficial change in BCVA from baseline to Week 48.
